Brachytherapy

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

Retrieved on: 
Monday, October 23, 2023
Capital Group Companies, FDA, Inc., NMSC, Cancer, Physician, ICAD, CE, Brachytherapy, Brain, Growth, Disease, Skin, ICAD Inc., Gynecologic cancer disparities in the United States, Patient, Prostate, Medical imaging, Elekta

Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023.

Key Points: 
  • Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023.
  • By acquiring the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, Elekta will be able to offer electronic brachytherapy technology to provide expanded access to treatment for a range of cancers.
  • Xoft's unique technology provides targeted cancer care expertly tailored to meet patients’ personalized needs.
  • We are pleased that Elekta will be acquiring the Xoft subsidiary including both the technology and team,” said Dana Brown, President & CEO of iCAD.

Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Bevacizumab, Neoplasm, FDA, Arm, PD-L1, Standard of care, Cervical cancer, Gynaecology, Hypothyroidism, Catholic higher education, Aes, NYSE, ESMO, Progression-free survival, Food, Trae tha Truth, Cisplatin, Congress, Chemoradiotherapy, MRK, PFS, European Society for Medical Oncology, Obstetrics, GOG, Brachytherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, HIV disease progression rates, Creighton University School of Medicine, CPS, ClinicalTrials.gov, Merck & Co., Risk, EBRT, Immunotherapy, University, European Network for Health Technology Assessment, Woman, Safety, European Society of Gynaecological Oncology, Cancer, Patient, OS, Death, Pharmaceutical industry, Merck

Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.

Key Points: 
  • Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.
  • ET during a late-breaking abstract proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2023 (abstract #LBA38).
  • After a median follow-up of 17.9 months (range, 0.9-31.0), the KEYTRUDA regimen reduced the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.55-0.89]; p=0.0020) versus concurrent chemoradiotherapy alone in these patients.
  • The 24-month PFS rate was 67.8% for patients who received the KEYTRUDA regimen compared to 57.3% for those who received concurrent chemoradiotherapy alone.

Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference

Retrieved on: 
Thursday, October 5, 2023
Recurrence, Conference, NYSE, UPMC Hillman Cancer Center, MS, Hereditary nonpolyposis colorectal cancer, Brain, Society, Brachytherapy, University, UPMC, Therapy, CATX, ASTRO, Neck, Lung, Head, Prostate cancer, Pelvic exenteration, Rate, Radiation, Patient, Medical imaging, MD

The first presentation, entitled “Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer,” was presented by Mohamed Abdelhakiem, MD from the UPMC Hillman Cancer Center in Pittsburgh, PA.

Key Points: 
  • The first presentation, entitled “Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer,” was presented by Mohamed Abdelhakiem, MD from the UPMC Hillman Cancer Center in Pittsburgh, PA.
  • The presentation described urinary data collected from 341 patients treated with Cesium-131 between 2006 and 2022.
  • The authors concluded that Cesium-131 brachytherapy is a promising alternative to pelvic exenteration, which can be a significant surgical procedure.
  • “We’re excited that UPMC’s long term data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ASTRO meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer.

Open Letter to ViewRay Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies

Retrieved on: 
Friday, October 13, 2023
Software, Research, Radiology, Oncology, Medical Devices, Technology, Hospitals, Health Technology, Science, Biotechnology, FDA, Health, Proton, Carbon, TBG, Cell, Radionuclide, Cyclotron, Blood, Proton therapy, Maintenance, IMRT, Brachytherapy

TeamBest Global Companies (TBG) have been in business since 1951—over 70 years—with many innovations in Brachytherapy, Teletherapy, IMRT treatment planning software, Heavy Ion 400 MeV ion, Rapid Cycling Medical Synchrotron Proton-to-Carbon, a range of cyclotrons from 1 MeV to 200 MeV for research, Radioisotope Production, Proton Therapy, Theranostics/Targeted Systemic Radiation Therapy, Blood, Animal Cell and Research Irradiators, etc.

Key Points: 
  • TeamBest Global Companies (TBG) have been in business since 1951—over 70 years—with many innovations in Brachytherapy, Teletherapy, IMRT treatment planning software, Heavy Ion 400 MeV ion, Rapid Cycling Medical Synchrotron Proton-to-Carbon, a range of cyclotrons from 1 MeV to 200 MeV for research, Radioisotope Production, Proton Therapy, Theranostics/Targeted Systemic Radiation Therapy, Blood, Animal Cell and Research Irradiators, etc.
  • I am saddened by ViewRay’s recent announcement that their operations will soon cease and that after October, their customers may not be able to receive support for service, maintenance, quality and regulatory issues, upgrades, etc.
  • TBG Companies have 1000s of Teletherapy units—Cobalt 60 Gamma Beam with IMRT capabilities on some, and 1000 plus X Ray, Cesium 137 Blood, Animal, Cell and Research Irradiators, among other products.

"Study Radiation Therapy With Erin" Podcast Fuels Global Interest as "2022-2023 Radiation Therapy Market Summary Report" is Released

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Acquisition, Breast cancer, IMV, RT, Data analysis, Brachytherapy, Radiation, Keiser University, IGRT, Cancer, EBRT, OEM, Woman, Patient, Medical imaging

The 2022-2023 Radiation Therapy Market Summary Report is a meticulous compilation of data, presenting a panoramic view of key radiation therapy technologies, ranging from external beam radiation therapy (EBRT) and image-guided radiotherapy (IGRT) to brachytherapy equipment and sophisticated simulators.

Key Points: 
  • The 2022-2023 Radiation Therapy Market Summary Report is a meticulous compilation of data, presenting a panoramic view of key radiation therapy technologies, ranging from external beam radiation therapy (EBRT) and image-guided radiotherapy (IGRT) to brachytherapy equipment and sophisticated simulators.
  • Holistic View of Radiation Therapy: The report comprehensively covers the range of radiation therapy technologies used in treating cancer patients, highlighting trends in patient volume, installed equipment, market share, and more.
  • For businesses, entrepreneurs, and managers in the healthcare sector, the 2022-2023 Radiation Therapy Market Summary Report is more than just data; it's the roadmap to understanding and navigating the rapidly evolving world of radiation therapy.
  • To invest in your business's future and to gain a robust understanding of the radiation therapy market, make sure to acquire the 2022-2023 Radiation Therapy Market Summary Report.

GT Medical Technologies, Inc. Presents New Data Further Demonstrating High Local Control for the Treatment of Recurrent Brain Metastases at the ASTRO 2023 Annual Meeting

Retrieved on: 
Monday, October 2, 2023
San Diego Convention Center, Brain, Radiation, Q&A, American Society for Radiation Oncology, ASTRO, Booth, Radiation therapy, Barrow Neurological Institute, Incidence, Publication, MD, Patient, Baptist Health, Annual general meeting, Poster, FDA, Society, Safety, Medical imaging, Medical device, Brachytherapy, Radiosurgery

TEMPE, Ariz., Oct. 2, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced interim findings of a multi-institutional study that demonstrates high local control for the treatment of recurrent brain metastases in patients, adding to the growing evidence of the efficacy and safety of its FDA-approved GammaTile® Therapy at the American Society for Radiation Oncology's (ASTRO) 65th Annual Meeting.

Key Points: 
  • None of the patients experienced adverse effects from the radiation treatment in follow-ups, which had a median time of four months post-surgery.
  • "This robust emerging scientific data reinforces the impact GammaTile Therapy has on local control for patients with brain metastases.
  • The poster, titled: "Surgically Targeted Radiation Therapy (STaRT) for Brain Metastases: Initial Experience from a Prospective Multi-institutional Registry" will be available on the ASTRO Annual Meeting Portal .
  • The results showed that GammaTile for operable recurrent brain metastases was associated with superior local control compared to the first course of external beam radiotherapy in the series.

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Wednesday, September 20, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, MSD, Bevacizumab, Progression-free survival, Neoplasm, MRK, Immunotherapy, PFS, Merck & Co., HIV disease progression rates, Cervical cancer, Patient, CPS, Brachytherapy, PDUFA, EBRT, FDA, Chemoradiotherapy, Recurrence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PD-L1, NYSE, Food, Disease, Pharmaceutical industry, Merck

The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone.

Key Points: 
  • The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone.
  • If approved, this would be Merck’s third approved indication in cervical cancer and first in an earlier stage of the disease.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2024.
  • “If approved, KEYTRUDA will be the first immunotherapy available for patients with newly diagnosed high-risk locally advanced cervical cancer.

Renowned Radiation Oncologist Joins NYU Langone Perlmutter Cancer Center as Vice Chair for Academic and Faculty Affairs, Director of Brachytherapy

Retrieved on: 
Monday, September 11, 2023
Faculty, Radiation, NYU, Quality of life, National Cancer Institute, Research, Prostate, Radiation therapy, Doctor of Philosophy, MRI, Memorial Sloan Kettering Cancer Center, MD, Patient, Memorial, Cancer, NYU Langone Health, Diagnosis, Neoplasm, Urology, Prostate cancer, Medical imaging, Brachytherapy

NEW YORK, Sept. 11, 2023 /PRNewswire/ -- Michael J. Zelefsky, MD, a renowned leader in radiation oncology, is joining the NYU Langone Perlmutter Cancer Center , as Director of Brachytherapy and Vice Chair for Academic and Faculty Affairs in NYU Grossman School of Medicine's Department of Radiation Oncology , effective September 11, in a move to enhance its position as a leader in prostate cancer treatment.

Key Points: 
  • NEW YORK, Sept. 11, 2023 /PRNewswire/ -- Michael J. Zelefsky, MD, a renowned leader in radiation oncology, is joining the NYU Langone Perlmutter Cancer Center , as Director of Brachytherapy and Vice Chair for Academic and Faculty Affairs in NYU Grossman School of Medicine's Department of Radiation Oncology , effective September 11, in a move to enhance its position as a leader in prostate cancer treatment.
  • He comes to NYU Langone from Memorial Sloan-Kettering Cancer Center, where he held major leadership roles.
  • "We are extremely excited to have Dr. Zelefsky join us," says Benjamin G. Neel, MD, PhD , director of the Perlmutter Cancer Center.
  • As a National Cancer Institute–designated comprehensive cancer center, we are proud to be on the cutting edge of bringing new, improved treatments to patients."

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Friday, August 11, 2023
GMP, Mayo Clinic, GE HealthCare, Safety, Glomus tumor, Doctor of Philosophy, Audit committee, Medicare, Journal, CATX, Patient, Investment, RLS, R, ED, NYSE, Brain, Prostate cancer, Centers for Medicare & Medicaid Services, University, Viewpoint, Fortis Healthcare, Research, Nuclear medicine, Rated R, Radiosurgery, Radiation, Knowledge, Growth, FDA, Bander, SPECT, GT, Roche, Isotopes of thorium, USP, 1991 World Sportscar Championship, Documentation, International Symposium on Endovascular Therapy, Neurosurgery, Therapy, Joint Commission, Isotopes of caesium, SNMMI, MC1R, Molecular imaging, PET, University of Iowa, CDMO, Melanoma, Medical imaging, Pharmaceutical industry, Management, Health insurance, MD, Brachytherapy, Operation

RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.

Key Points: 
  • RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports second quarter financial results for the period ended June 30, 2023 and recent business highlights.
  • With a strong team in place, we’re focused on securing new business and re-gaining old business.
  • For the first half of fiscal 2023 ended June 30, 2023, revenue decreased 23% to $4.2 million versus $5.4 million in the prior year comparable period.
  • Prostate brachytherapy represented 42% of total revenue for the first six months of fiscal 2023 compared to 73% for the first six months of fiscal 2022.

Prostate cancer treatment is not always the best option – a cancer researcher walks her father through his diagnosis

Retrieved on: 
Tuesday, August 8, 2023
Infection, Radiation, Pelvic floor dysfunction, Awareness, Life, Friends, Prostate cancer, Neoplasm, Anxiety, BPH, Survival, Cancer, Prognosis, Research, Overdiagnosis, Prostate, Inflammation, Incidence, Man, Patient, Time, Risk, Blood, Brachytherapy, Observation, Diagnosis, Death, Health literacy, Family, News, PSA, Roger Hawkins (drummer), Gene, Biopsy, Disease, Dairy, Dentistry, Medical imaging, Pharmaceutical industry, Birth control, Nursing

As a cancer researcher who knows very well about the high incidence and decreased survival rates of prostate cancer in the Caribbean, I anguished over these words.

Key Points: 
  • As a cancer researcher who knows very well about the high incidence and decreased survival rates of prostate cancer in the Caribbean, I anguished over these words.
  • Even though I study cancer in my day job, I struggled to take in this news.
  • “They are recommending treatment.” However, I understood from my work that not undergoing treatment was also an option.

Prostate cancer diagnosis

    • His battle with his prostate health started 10 years ago with an initial diagnosis of benign prostate hyperplasia, or BPH.
    • Although research suggests that the factors that contribute to BPH similarly contribute to prostate cancer, there is no evidence that an enlarged prostate will necessarily develop into cancer.
    • PSA is a protein that both normal and cancerous prostate cells produce, and elevated amounts are considered red flags for prostate cancer.

Cancer risk categorization

    • I explained that categorizing how aggressive the cancer is and how far it has spread can help determine the best course of treatment.
    • Some patients with early-stage or intermediate-risk prostate cancer undergo additional treatment, including surgery, radiation or radioactive seed implants called brachytherapy.
    • Patients with late-stage prostate cancer typically undergo hormone therapy along with surgery or radiation, or chemotherapy with or without radiation.

Prostate cancer screening problems

    • Even with all my expertise studying cancer genetics and working with cancer patients, I couldn’t help second-guessing our decisions, and I sometimes questioned our decision not to immediately treat his cancer.
    • Nearly half of all patients with prostate cancer are overdiagnosed, often leading to overtreatment.
    • Several studies in the U.S. have shown that patients with early-stage prostate cancer have a good prognosis, and the cancer rarely progresses further.
    • Overdiagnosis and overtreatment of prostate cancer led the U.S. Preventive Services Task Force to recommend against PSA-based screening in 2012, with caveats for high-risk groups including African American men and those with a family history of prostate cancer.
    • Those recommendations have resulted in reduced screening and increased prostate cancer diagnoses.

Surviving prostate cancer

    • I still worry about my father’s diagnosis, because his cancer is at risk for progression.
    • His doctors are monitoring his PSA levels as part of his survivorship plan, which is a record of information about his cancer diagnosis, treatment history and potential follow-up tests.
    • Many were under the impression that prostate cancer required immediate treatment.